Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study.

Autor:	Santos LPA; Departamento de Ginecologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brasil. Electronic address: liani.paty@gmail.com., Bonduki CE; Departamento de Ginecologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brasil., Dardes RCM; Departamento de Ginecologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brasil., Heinke T; Departamento de Patologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brasil., Patriarca MT; Departamento de Ginecologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brasil.
Jazyk:	angličtina
Zdroj:	Clinics (Sao Paulo, Brazil) [Clinics (Sao Paulo)] 2022 Oct 01; Vol. 77, pp. 100116. Date of Electronic Publication: 2022 Oct 01 (Print Publication: 2022).
DOI:	10.1016/j.clinsp.2022.100116
Abstrakt:	Objectives: In this pilot, prospective, randomized, double-blind study, the authors compared the efficacy of oxytocin with promestriene in improving vaginal atrophy of Genitourinary Syndrome of Menopause (GSM). Methods: A total of 51 postmenopausal women with symptoms of GSM were evaluated. They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness. Results: After the use of the medications, both groups showed significant improvement in the three evaluated FSFI domains (p < 0.05) and there was no significant difference between the groups (p > 0.05). On clinical examination, the medications improved all the evaluated parameters but without statistical significance (p > 0.05). The evaluation of the thickness of the vaginal epithelium showed that both treatments led to increase in the vaginal epithelium (p < 0.05); however, the efficacy of promestriene was higher than that of oxytocin (p < 0.05). Conclusions: Both medications were effective, however, studies with larger samples and longer follow-ups are needed to confirm the clinical applicability. Competing Interests: Conflicts of interest The authors declare no conflicts of interest. (Copyright © 2022 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu